Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel.

Hagihara K, Kazui M, Kurihara A, Kubota K, Ikeda T.

Drug Metab Dispos. 2011 Feb;39(2):208-14. doi: 10.1124/dmd.110.035196. Epub 2010 Oct 29.

2.

The intestine as an important contributor to prasugrel active metabolite formation in vivo.

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Izumi T, Ikeda T, Kurihara A.

Drug Metab Dispos. 2011 Apr;39(4):565-70. doi: 10.1124/dmd.110.035956. Epub 2010 Dec 28.

3.

Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2010 Jun;38(6):898-904. doi: 10.1124/dmd.110.032086. Epub 2010 Mar 12.

4.

Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate.

Hagihara K, Kazui M, Kurihara A, Ikeda T, Izumi T.

Drug Metab Dispos. 2012 Sep;40(9):1854-9. doi: 10.1124/dmd.112.045914. Epub 2012 Jun 25.

5.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ.

Drug Metab Dispos. 2006 Apr;34(4):600-7. Epub 2006 Jan 13.

6.

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA.

Drug Metab Dispos. 2008 Jul;36(7):1227-32. doi: 10.1124/dmd.107.020248. Epub 2008 Mar 27.

7.

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2009 Nov;37(11):2145-52. doi: 10.1124/dmd.109.028498. Epub 2009 Aug 24.

8.

Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.

Chen CH, Yang JC, Uang YS, Lin CJ.

Biopharm Drug Dispos. 2012 Jul;33(5):278-83. doi: 10.1002/bdd.1795. Epub 2012 Jun 29.

PMID:
22623337
9.

The disposition of prasugrel, a novel thienopyridine, in humans.

Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ.

Drug Metab Dispos. 2007 Jul;35(7):1096-104. Epub 2007 Apr 2.

11.

Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, Kurihara A, Okazaki O, Farid NA, Ikeda T.

Xenobiotica. 2009 Mar;39(3):218-26. doi: 10.1080/00498250802650077.

PMID:
19280520
12.

Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.

Dansette PM, Rosi J, Debernardi J, Bertho G, Mansuy D.

Chem Res Toxicol. 2012 May 21;25(5):1058-65. doi: 10.1021/tx3000279. Epub 2012 Apr 18.

PMID:
22482514
13.

Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel.

Dansette PM, Thébault S, Bertho G, Mansuy D.

Chem Res Toxicol. 2010 Jul 19;23(7):1268-74. doi: 10.1021/tx1001332.

PMID:
20557086
14.

[Prasugrel, a new thienopyridine].

Schrör K, Huber K.

Hamostaseologie. 2007 Dec;27(5):351-5. German.

PMID:
18060245
15.

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F.

Thromb Haemost. 2005 Sep;94(3):593-8.

PMID:
16268477
16.

Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel.

Kazui M, Hagihara K, Izumi T, Ikeda T, Kurihara A.

Drug Metab Dispos. 2014 Jul;42(7):1138-45. doi: 10.1124/dmd.114.057661. Epub 2014 Apr 14.

17.

Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor.

Algaier I, Jakubowski JA, Asai F, von Kügelgen I.

J Thromb Haemost. 2008 Nov;6(11):1908-14. doi: 10.1111/j.1538-7836.2008.03136.x. Epub 2008 Aug 22.

PMID:
18752581
18.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Payne CD, Salazar DE, Winters KJ.

Curr Med Res Opin. 2008 Aug;24(8):2251-7. doi: 10.1185/03007990802205985.

PMID:
18786302
19.

Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

Dobesh PP.

Pharmacotherapy. 2009 Sep;29(9):1089-102. doi: 10.1592/phco.29.9.1089.

PMID:
19698014
20.

Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.

Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J.

Metabolism. 2011 Nov;60(11):1584-9. doi: 10.1016/j.metabol.2011.03.015. Epub 2011 May 6.

PMID:
21550074
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk